Siemens Healthineers AG (SEMHF) Receives a Buy from Jefferies

Jefferies analyst James Vane maintained a Buy rating on Siemens Healthineers AG (SEMHFResearch Report) today and set a price target of EUR53.00. The company’s shares closed last Monday at $46.94.

According to TipRanks, Vane is ranked #6440 out of 7941 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Siemens Healthineers AG with a $59.26 average price target, implying a 26.25% upside from current levels. In a report released today, J.P. Morgan also maintained a Buy rating on the stock with a EUR63.10 price target.

See today’s best-performing stocks on TipRanks >>

Based on Siemens Healthineers AG’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $5.19 billion and a net profit of $363 million. In comparison, last year the company earned a revenue of $5 billion and had a net profit of $390 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Siemens Healthineers AG operates as a holding company. The company intends to operate the digital services business. It operates through the following business segments: Imaging, Diagnotics, and Advanced Therapies. The Imaging segment offers diagnostic imaging products and a broad portfolio of advanced imaging and ultrasound systems and solutions. The Diagnostics segment offers products, services and solutions, including a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Advanced Therapies is a supplier of advanced therapy products, services and solutions to the therapy departments of healthcare providers. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Erlangen, Germany.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More